Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00701259 · ClinicalTrials.gov registry record · Phase 3
Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn
A Phase 3 study of Frequent Heartburn, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 852
- Enrollment target
- 1
- Study location
NCT00701259 is a Phase 3 study of Frequent Heartburn that has completed, run by Novartis. The registered enrollment target is 852 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00701259, a Phase 3 study of Frequent Heartburn, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 852 participants
- Enrollment target
- 1
- Study location
Study Summary
Heartburn, a burning sensation in the chest or throat, occurs in many individuals when acidic stomach contents move upward into the esophagus from the stomach. This study will investigate the safety and efficacy of lansoprazole 15 mg or 30 mg administered once a day in preventing frequent nighttime heartburn.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Lansoprazole
Study Locations (1)
New Jersey
- Not applicable - enrollment complete - Parsippany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 852 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00701259
The ClinicalTrials.gov registry entry for NCT00701259 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 852 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Frequent Heartburn appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00701259 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00701259 about?
NCT00701259 is a clinical study titled "Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn". Heartburn, a burning sensation in the chest or throat, occurs in many individuals when acidic stomach contents move upward into the esophagus from the stomach. This study will investigate the safety and efficacy of lansoprazole 15 mg or 30 mg administered once a day in preventing frequent nighttime ...
What is the current status of trial NCT00701259?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 852 participants. The study started on 2007-01. Estimated completion is 2007-08.
What conditions does trial NCT00701259 study?
This clinical trial studies the following conditions: Frequent Heartburn.
What interventions are being tested in trial NCT00701259?
The interventions under investigation include: placebo (DRUG), Lansoprazole (DRUG).
Who is sponsoring clinical trial NCT00701259?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00701259 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.